KR20170102887A - 브루톤 티로신 키나제 저해제의 합성 - Google Patents

브루톤 티로신 키나제 저해제의 합성 Download PDF

Info

Publication number
KR20170102887A
KR20170102887A KR1020177019206A KR20177019206A KR20170102887A KR 20170102887 A KR20170102887 A KR 20170102887A KR 1020177019206 A KR1020177019206 A KR 1020177019206A KR 20177019206 A KR20177019206 A KR 20177019206A KR 20170102887 A KR20170102887 A KR 20170102887A
Authority
KR
South Korea
Prior art keywords
compound
formula
ibrutinib
pyrazolo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177019206A
Other languages
English (en)
Korean (ko)
Inventor
시릴 벤하임
웨이 첸
에릭 골드만
안드라스 호르바트
필립 피에
마크 에스 스미스
에릭 제이 베르너
Original Assignee
파마싸이클릭스 엘엘씨
잔센파마슈티카엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마싸이클릭스 엘엘씨, 잔센파마슈티카엔.브이. filed Critical 파마싸이클릭스 엘엘씨
Publication of KR20170102887A publication Critical patent/KR20170102887A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177019206A 2015-01-14 2016-01-14 브루톤 티로신 키나제 저해제의 합성 Ceased KR20170102887A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
KR20170102887A true KR20170102887A (ko) 2017-09-12

Family

ID=56406389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177019206A Ceased KR20170102887A (ko) 2015-01-14 2016-01-14 브루톤 티로신 키나제 저해제의 합성

Country Status (16)

Country Link
US (6) US20180009814A1 (https=)
EP (1) EP3245208A4 (https=)
JP (2) JP2018502077A (https=)
KR (1) KR20170102887A (https=)
CN (2) CN113816962A (https=)
AU (2) AU2016206693A1 (https=)
BR (1) BR112017015206B1 (https=)
CA (2) CA3210320A1 (https=)
HK (1) HK1246293A1 (https=)
IL (4) IL308276A (https=)
MA (1) MA41350A (https=)
MX (2) MX366827B (https=)
RU (1) RU2017128308A (https=)
SG (2) SG10201906517VA (https=)
WO (1) WO2016115356A1 (https=)
ZA (1) ZA201704338B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210080468A (ko) * 2018-10-22 2021-06-30 화이자 인코포레이티드 피롤로[2,3-d]피리미딘 토실레이트 염, 이의 결정질 형태, 이의 제조 방법 및 이에 대한 중간체

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214532B2 (en) * 2015-02-12 2019-02-26 Shanghai Dude Medical Science and Technology Co., Ltd. Process for preparing ibrutinib
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
JP7166331B2 (ja) 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
WO2020095452A1 (ja) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
AU2020280904A1 (en) * 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
AU2020278162A1 (en) 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
WO2022157250A1 (en) 2021-01-21 2022-07-28 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
BRPI0418078A8 (pt) * 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN104507946A (zh) * 2012-07-30 2015-04-08 康塞特医药品有限公司 氘代依鲁替尼
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210080468A (ko) * 2018-10-22 2021-06-30 화이자 인코포레이티드 피롤로[2,3-d]피리미딘 토실레이트 염, 이의 결정질 형태, 이의 제조 방법 및 이에 대한 중간체

Also Published As

Publication number Publication date
WO2016115356A1 (en) 2016-07-21
US20200347064A1 (en) 2020-11-05
MA41350A (fr) 2017-11-21
CN113816962A (zh) 2021-12-21
IL253020A0 (en) 2017-08-31
US20240158400A1 (en) 2024-05-16
ZA201704338B (en) 2023-10-25
SG11201705678YA (en) 2017-08-30
RU2017128308A (ru) 2019-02-14
BR112017015206A2 (pt) 2018-06-19
HK1246293A1 (zh) 2018-09-07
IL274716A (en) 2020-07-30
CA3210320A1 (en) 2016-07-21
IL308276A (en) 2024-01-01
RU2017128308A3 (https=) 2019-10-24
AU2020230323A1 (en) 2020-10-01
AU2016206693A1 (en) 2017-07-13
EP3245208A1 (en) 2017-11-22
MX2019008815A (es) 2019-09-26
BR112017015206B1 (pt) 2023-04-11
MX394327B (es) 2025-03-24
EP3245208A4 (en) 2018-10-17
SG10201906517VA (en) 2019-08-27
US20250197404A1 (en) 2025-06-19
JP2018502077A (ja) 2018-01-25
MX366827B (es) 2019-07-25
MX2017009154A (es) 2017-10-12
JP2021035947A (ja) 2021-03-04
CN107108640A (zh) 2017-08-29
US20190367518A1 (en) 2019-12-05
US20220098200A1 (en) 2022-03-31
CA2971460C (en) 2023-10-10
US20180009814A1 (en) 2018-01-11
CA2971460A1 (en) 2016-07-21
IL322449A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
KR20170102887A (ko) 브루톤 티로신 키나제 저해제의 합성
JP6133931B2 (ja) メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル］ピリミジン−５−イル｝メチルカルバメートの調製方法および医薬上活性な化合物として用いるためのその精製方法
EP3215493B1 (en) Synthesis of copanlisib and its dihydrochloride salt
TW201825491A (zh) 製備細胞凋亡誘導劑的方法
KR20190018021A (ko) 치환된 5-플루오로-1h-피라졸로피리딘의 제조 방법
EP3848361B1 (en) Method of producing tetracyclic compound
US12084454B2 (en) Process for preparing BTK inhibitors
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
KR20150114471A (ko) 살선충성 설폰아미드의 제조 방법
AU2009298757B2 (en) Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
KR20160118359A (ko) 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조
KR20090116753A (ko) 3-메틸-4-페닐이속사졸로〔3,4-ｄ〕피리다진-7(6Ｈ)-온의 신규한 제조 방법
WO2016071382A1 (en) Synthesis of pi3k inhibitor and salts thereof
WO2022032644A1 (zh) 一种取代的咪唑并[1,2-a]吡啶-2-基酰胺化合物的制备方法及其中间体
KR20200092945A (ko) 레날리도마이드의 결정형
JP4596804B2 (ja) シラザプリルの製造方法
BR122022026564B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (ibrutinibe) e compostos
TW202134242A (zh) 用於生產式(i)之方法及中間體

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20260226

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2017 7019206

Appeal request date: 20241108

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101002377

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024101002377; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : APPEAL AGAINST DECISION TO DECLINE REFUSAL